NCT04088500View on ClinicalTrials.gov

A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

September 3, 2020

Primary Completion Date

November 15, 2021

Study Completion Date

November 15, 2021

Conditions
Renal Cell Carcinoma
Interventions
BIOLOGICAL

Nivolumab

Specific dose on specific days

BIOLOGICAL

Ipilimumab

Specific dose on specific days

Trial Locations (12)

63108

Washington University School of Medicine in St. Louis WUSTL, St Louis

T3B 3L1

Local Institution, Calgary

T6G 1Z2

Cross Cancer Institute, Edmonton

V5Z 4E6

BC Cancer Agency - Vancouver Centre, Vancouver

B3H 1V7

Atlantic Clinical Cancer Research Unit, Halifax

L8V 5C2

Hamilton Health Sciences (HHS) - Juravinski Cancer Centre (JCC), Hamilton

M4N 3M5

Toronto Sunnybrook Regional Cancer Ctr, Toronto

M5G 2M9

Local Institution, Toronto

H2X 3E4

Local Institution, Montreal

H3T 1E2

Local Institution - 0005, Montreal

G2L 2Z3

Local Institution, Québec

J1H 5N4

Local Institution - 0006, Sherbrooke

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04088500 - A Study of Combination Nivolumab and Ipilimumab Retreatment in Patients With Advanced Renal Cell Carcinoma | Biotech Hunter | Biotech Hunter